DIFICID (fidaxomicin) is currently FDA approved to treat Clostridium difficile-associated diarrhea (CDAD) in adult patients 18 years of age and older.
Currently, clinical trials are ongoing to assess the efficacy and safety of DIFICID, in either a tablet and oral suspension formulation, in pediatric patients with CDAD.
In addition, DIFICID is currently in clinical trials to determine the efficacy of use as a prophylaxis against CDAD in adult patients undergoing hematopoietic stem cell transplantation (HSCT).
*Please note – The C Diff Foundation does not endorse this product or any product and this posting is strictly for informational purposes only.
Sanofi Pasteur’s Clinical Vaccine Trial for Prevention of C.diff Now in Phase III Stage
Sanofi Pasteur, one of the world’s largest vaccine manufacturers, is developing a vaccine for prevention of Clostridium difficile.
Because of the unmet medical need regarding this disease, in 2010, The U.S. Food and Drug Administration (FDA) granted fast-track designation to Sanofi Pasteur’s investigational Clostridium difficile vaccine candidate. The vaccine is now in the Phase III stages of its Clinical Vaccine Trial and is looking for volunteers in several countries to participate in this preventative vaccine trial.
For more information regarding the Cdiffense Cdiff vaccine trial and trial centers, please visit http://www.cdiffense.org